Delivery Hero Sells Taiwan Foodpanda to Grab for $600 Million in Debt-Reduction Push 
Moderna Stock Drops After FDA Declines Review of mRNA Flu Vaccine 
Novartis’ Vanrafia Shows Strong Phase 3 Results in IgA Nephropathy, Paving Way for Full Approval 
FDA Biologics Chief Vinay Prasad to Leave Agency in April Amid Policy Disputes 
RFK Jr. Overhauls Federal Autism Panel, Sparking Medical Community Backlash 
CDC Acting Director Urges Measles Vaccination as U.S. Cases Surge in 2026 
Citi Names Eric Farina and Rob Cascarino to Lead Global Infrastructure Financing Group 
SK Hynix Eyes Up to $14 Billion U.S. IPO to Fund AI Chip Expansion 
Rio Tinto's Resolution Copper Mine: U.S. Smelting Challenges and Global Operations Update 
Nanya Technology Shares Surge 10% After $2.5 Billion Private Placement from Sandisk and Cisco 
Berkshire Hathaway and Tokio Marine Form Major Strategic Insurance Partnership 
SpaceX IPO Filing Expected This Week as Valuation Could Surpass $75 Billion 
Meta Ties Executive Pay to Aggressive Stock Price Targets in Major Retention Push 
Innate Pharma Reports 55% Revenue Drop and €49.2M Net Loss for 2025 
GlaxoSmithKline (GSK) and Eli Lilly are making major U.S. manufacturing commitments as global pharmaceutical companies expand domestic operations in response to possible tariffs on imported medicines. According to The Wall Street Journal, more than a dozen drugmakers have pledged over $350 billion in U.S. investments this decade to strengthen local supply chains and reduce tariff risks.
GSK (LON:GSK) revealed plans to spend $30 billion in the United States over the next five years, focusing on research, supply-chain infrastructure, and new production facilities. The investment includes $1.2 billion for a new factory near Philadelphia dedicated to developing treatments for respiratory illnesses and cancer. The move positions GSK to boost U.S. drug production while creating new jobs in the biopharma sector.
Meanwhile, Eli Lilly (NYSE:LLY) announced a $5 billion investment to build a state-of-the-art plant near Richmond, Virginia. The facility will specialize in manufacturing monoclonal antibodies and bioconjugates, critical therapies in oncology and immunology. Once operational, the plant is expected to employ approximately 650 workers, enhancing Lilly’s domestic manufacturing footprint and supporting innovation in biologic medicines.
The surge in U.S. pharmaceutical investments comes as the Trump administration considers imposing tariffs on imported drugs, with rates potentially climbing to 250% within 18 months. Such measures could significantly impact global supply chains, pushing companies to accelerate onshore production strategies.
By committing billions to U.S. manufacturing, GSK and Eli Lilly join a broader trend of pharmaceutical giants prioritizing local capacity. These investments are expected to safeguard supply resilience, stimulate job creation, and position drugmakers to better navigate policy changes affecting the global pharmaceutical market.
